Inositec
Manufacturing · 1-10 Employees
View Company Info for Free
Overview
Phone Number
+41 442710755Website
www.inositec.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Inositec
Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable InosituneÔ technology to adjust the chemical and physical properties of inositol phosphate (IP6) analogs, Inositec is developing a novel class of drugs currently focusing on high-unmet medical needs related to calcification disorders. The lead compound INS-3001 is a cardiovascular calcification inhibitor in development for aortic valve stenosis. Inositec was founded in December 2015 based on the award-winning research of Dr. Mattias Ivarsson, Prof. Jean-Christophe Leroux and Prof. Bastien Castagner at ETH Zurich, Switzerland.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inositec your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Inositec has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Inositec had a recent Job posting/layoffs
Product Launch: Get notified when Inositec launches new products
Check out if Inositec is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Inositec
Earning: See what the market has to say on Inositec recently announced quarterly report
Inositec, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Inositec has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Inositec is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inositec is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inositec.
Inositec financials insights
Gather financial insights about Inositec, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Angel/Seed
$1.4M
Inositec Tech Stack
A closer look at the technologies used by Inositec
Inositec News & Media
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
ST. GALLEN, Switzerland & PALMA, Spain & ZURICH--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disInositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors
ZURICH--(BUSINESS WIRE)--Inositec has appointed Michael H. Davidson to its Board of DirectorsInositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
ZURICH--(BUSINESS WIRE)--US patent office has issued Inositec a patent covering its platform of inositol phosphate analogs and specifically INS-3001 a calcification inhibitor.Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications
ZURICH--(BUSINESS WIRE)--Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inositec
Sign Up For FreeTo access detailed company insights
Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable InosituneÔ technology to adjust the chemical and physical properties of inositol phosphate (IP6) analogs, Inositec is developing a novel class of drugs currently fo... Read More
